Erasca Inc - Asset Resilience Ratio
Erasca Inc (ERAS) has an Asset Resilience Ratio of 51.06% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Erasca Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Erasca Inc's Asset Resilience Ratio has changed over time. See what is Erasca Inc's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Erasca Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Erasca Inc (ERAS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $202.27 Million | 51.06% |
| Total Liquid Assets | $202.27 Million | 51.06% |
Asset Resilience Insights
- Very High Liquidity: Erasca Inc maintains exceptional liquid asset reserves at 51.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Erasca Inc Industry Peers by Asset Resilience Ratio
Compare Erasca Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Erasca Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Erasca Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.06% | $202.27 Million | $396.15 Million | +5.18pp |
| 2024-12-31 | 45.88% | $230.57 Million | $502.53 Million | -9.59pp |
| 2023-12-31 | 55.47% | $219.28 Million | $395.30 Million | +26.07pp |
| 2022-12-31 | 29.40% | $151.40 Million | $514.91 Million | +18.64pp |
| 2021-12-31 | 10.77% | $53.99 Million | $501.42 Million | -31.95pp |
| 2020-12-31 | 42.72% | $53.33 Million | $124.83 Million | +5.28pp |
| 2019-12-31 | 37.44% | $20.79 Million | $55.51 Million | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more